Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) Return on Sales (2016 - 2025)

Historic Return on Sales for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 0.19%.

  • Gyre Therapeutics' Return on Sales rose 800.0% to 0.19% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.1%, marking a year-over-year increase of 9100.0%. This contributed to the annual value of 0.16% for FY2024, which is 9200.0% up from last year.
  • Gyre Therapeutics' Return on Sales amounted to 0.19% in Q3 2025, which was up 800.0% from 0.06% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year Return on Sales high stood at 3.68% for Q3 2022, and its period low was 18.31% during Q1 2022.
  • Its 5-year average for Return on Sales is 3.73%, with a median of 0.06% in 2025.
  • In the last 5 years, Gyre Therapeutics' Return on Sales plummeted by -150400bps in 2021 and then surged by 184800bps in 2023.
  • Over the past 5 years, Gyre Therapeutics' Return on Sales (Quarter) stood at 8.32% in 2021, then surged by 97bps to 0.28% in 2022, then tumbled by -1222bps to 3.75% in 2023, then soared by 100bps to 0.02% in 2024, then skyrocketed by 1350bps to 0.19% in 2025.
  • Its Return on Sales was 0.19% in Q3 2025, compared to 0.06% in Q2 2025 and 0.17% in Q1 2025.